Faculty

Back to Index
Barbara Gitlitz, MD
Associate Professor of Clinical Medicine
Medicine
NOR 3440 Health Sciences Campus Los Angeles
+1 323 865 3906

Overview

After graduating from the State University of New York Stony Brook campus, Dr. Gitlitz moved out west to California. After completing a fellowship in Hematology Oncology and Translational Investigation at UCLA, she stayed on as an Assistant Professor. Much of her early clinical-translational work involved cancer immunotherapy including one of the first trials of a Dendritic Cell Vaccine for patients with kidney cancer. She then joined the Keck School of Medicine of USC as an Associate Professor to spearhead the USC oncology effort in lung cancer and head and neck cancer. Her most rewarding part of working at USC is being a member of multidisciplinary treatment teams; where medical oncologists, surgeons, radiation oncologists and other specialists can collaborate together on the best, individualized treatment plan for a patient. Her dedicated, compassionate clinical care has been noticed by the community as she has been consistently nominated to the list of Los Angeles Magazine Super Doctors, Pasadena Magazine Top Doctors, and US News Top Doctors.

She has received research grants from the American Cancer Society, the National Institute of Health and STOP cancer. Currently she is a member of the Stand Up 2 Cancer Epigenetics Dream Team where she will bring novel trials to treat cancer with combinations of immunotherapy and therapy to awaken important genes that are “turned off†by growing cancers. Dr. Gitlitz has a passion for working with scientists seeking ways to personalize therapy and bring novel drugs (clinical trials) to treat her patients. She believes that each person’s cancer may have unique molecular/genomic features to help guide the best treatment plan. Dr. Gitlitz is an accomplished author and has numerous articles published in peer reviewed cancer journals and she has written numerous book chapters. She has been invited to lecture at cancer conferences all across the United States and internationally.

Awards

STOP Cancer: David L. Ray Memorial Seed Grant, 2013

USC Norris Comprehensive Cancer Center: Stop Cancer Award, 2004-2009

STOP Cancer: Department, 2013

STOP Cancer: award conferred by, 2013

USC Norris Comprehensive Cancer Center: award conferred by, 2004-2009

USC Norris Comprehensive Cancer Center: ORNG Application Instance for Person, 2004-2009

STOP Cancer: ORNG Application Instance for Person, 2013

STOP Cancer: full name, 2013

USC Norris Comprehensive Cancer Center: full name, 2004-2009

STOP Cancer: person in primary position, 2013

STOP Cancer: last name, 2013

USC Norris Comprehensive Cancer Center: last name, 2004-2009

STOP Cancer: HR job title, 2013

USC Norris Comprehensive Cancer Center: HR job title, 2004-2009

USC Norris Comprehensive Cancer Center: ORNG Application URL, 2004-2009

STOP Cancer: ORNG Application URL, 2013

USC Norris Comprehensive Cancer Center: sort order, 2004-2009

STOP Cancer: sort order, 2013

USC Norris Comprehensive Cancer Center: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1146-120, 2004-2009

STOP Cancer: http://orng.info/ontology/orng#ApplicationInstance^^ORNG Application Instance^^1146-120, 2013

STOP Cancer: email address, 2013

USC Norris Comprehensive Cancer Center: email address, 2004-2009

USC Norris Comprehensive Cancer Center: start date, 2004-2009

STOP Cancer: start date, 2013

STOP Cancer: ClinicalTrials, 2013

USC Norris Comprehensive Cancer Center: ClinicalTrials, 2004-2009

USC Norris Comprehensive Cancer Center: end date, 2004-2009

STOP Cancer: has ORNG Application Instance Data, 2013

USC Norris Comprehensive Cancer Center: Associate Professor, 2004-2009

STOP Cancer: Associate Professor, 2013

USC Norris Comprehensive Cancer Center: label, 2004-2009

STOP Cancer: label, 2013

USC Norris Comprehensive Cancer Center: Faculty Rank, 2004-2009

STOP Cancer: Faculty Rank, 2013

STOP Cancer: is primary position, 2013

USC Norris Comprehensive Cancer Center: is primary position, 2004-2009

STOP Cancer: Gitlitz, Barbara, 2013

USC Norris Comprehensive Cancer Center: Gitlitz, Barbara, 2004-2009

STOP Cancer: Agent, 2013

USC Norris Comprehensive Cancer Center: Agent, 2004-2009

USC Norris Comprehensive Cancer Center: has ORNG Application Instance Data, 2004-2009

USC Norris Comprehensive Cancer Center: Organization, 2004-2009

STOP Cancer: Organization, 2013

STOP Cancer: has faculty rank, 2013

USC Norris Comprehensive Cancer Center: has faculty rank, 2004-2009

USC Norris Comprehensive Cancer Center: ORNG Application Instance Data value, 2004-2009

STOP Cancer: ORNG Application Instance Data value, 2013

STOP Cancer: Keck School of Medicine of USC, 2013

USC Norris Comprehensive Cancer Center: Keck School of Medicine of USC, 2004-2009

USC Norris Comprehensive Cancer Center: ct_data, 2004-2009

STOP Cancer: ct_data, 2013

USC Norris Comprehensive Cancer Center: Position, 2004-2009

STOP Cancer: Position, 2013

STOP Cancer: first name, 2013

Publications

. View in: PubMed

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Lung Cancer. 2017 Apr; 106:110-114. View in: PubMed

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. J Thorac Oncol. 2016 Nov 27. View in: PubMed

P1. 49 (also presented as PD1. 05): The Genomics of Young Emergent Lung Cancer: Track: Advanced NSCLC. J Thorac Oncol. 2016 Oct; 11(10S):S214. View in: PubMed

PD1. 05 (also presented as P1. 49): The Genomics of Young Emergent Lung Cancer. J Thorac Oncol. 2016 Oct; 11(10S):S174. View in: PubMed

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016 Apr; 27(4):693-9. View in: PubMed

Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar; 17(2):113-118. e2. View in: PubMed

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 1; 21(19):4321-6. View in: PubMed

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer. 2015 May; 88(2):231-4. View in: PubMed

Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015 Jan; 10(1):110-5. View in: PubMed

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. View in: PubMed

Eribulin: a new-generation antimicrotubule agent in lung cancer therapy. Future Oncol. 2014 Oct; 10(12):1913-24. View in: PubMed

A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Apr; 9(4):577-82. View in: PubMed

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014 Feb; 24(2):232-40. View in: PubMed

Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. Oncologist. 2014; 19(2):175-6. View in: PubMed

Epigenetic therapy in lung cancer. Front Oncol. 2013; 3:135. View in: PubMed

Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80. View in: PubMed

Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol. 2012 Apr; 23(4):1023-9. View in: PubMed

A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8. View in: PubMed

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2012 Mar; 69(3):835-43. View in: PubMed

Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol. 2012 Mar; 7(3):579-86. View in: PubMed

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res. 2012 Feb 15; 18(4):1092-100. View in: PubMed

Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. View in: PubMed

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res. 2011 May 15; 17(10):3304-15. View in: PubMed

Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer. 2011 Feb 15; 117(4):809-18. View in: PubMed

Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. View in: PubMed

Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. View in: PubMed

Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010 Nov; 5(11):1835-40. View in: PubMed

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jun 20; 28(18):3076-83. View in: PubMed

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jan 1; 28(1):56-62. View in: PubMed

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009 Jan; 4(1):97-101. View in: PubMed

Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother. 2005 Jul-Aug; 28(4):376-81. View in: PubMed

Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother. 2004 May-Jun; 27(3):240-53. View in: PubMed

Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment. Radiology. 2004 May; 231(2):359-64. View in: PubMed

Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients. Int J Cancer. 2003 Nov 1; 107(2):256-61. View in: PubMed

A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer. 2003 Nov 1; 98(9):1863-9. View in: PubMed

A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother. 2003 Sep-Oct; 26(5):412-9. View in: PubMed

Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am. 2003 Aug; 30(3):589-600. View in: PubMed

Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003 Jun 15; 97(12):2995-3002. View in: PubMed

Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003 Jun; 169(6):2076-83. View in: PubMed

Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003 Mar; 169(3):909-16. View in: PubMed

Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer. J Immunother. 2003 Mar-Apr; 26(2):171-8. View in: PubMed

Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003 Feb; 61(2):314-9. View in: PubMed

Cell, gene and vaccine based strategies in kidney cancer. Cancer Treat Res. 2003; 116:183-98. View in: PubMed

Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002 Mar 1; 20(5):1368-74. View in: PubMed

Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol. 2002 Jan; 167(1):71-4. View in: PubMed

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res. 2001 Nov 1; 61(21):7925-33. View in: PubMed

Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4. 5 rather than 7 cm. better correlates with clinical outcome. J Urol. 2001 Jul; 166(1):54-8. View in: PubMed

Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol. 2001 May; 19(2):141-7. View in: PubMed

Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001 Mar 15; 19(6):1649-57. View in: PubMed

Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients. Cancer J. 2001 Mar-Apr; 7(2):112-20. View in: PubMed

Dendritic cell-based immunotherapy of renal cell carcinoma. Curr Urol Rep. 2001 Feb; 2(1):46-52. View in: PubMed

Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J. 2000 Jul-Aug; 6(4):220-33. View in: PubMed

Adoptive cellular therapy. Semin Oncol. 2000 Apr; 27(2):221-33. View in: PubMed

Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res. 2000 Apr 1; 60(7):1934-41. View in: PubMed

Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma. J Immunother. 2000 Jan; 23(1):83-93. View in: PubMed

Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res. 1999 Feb; 5(2):445-54. View in: PubMed

Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma. J Immunother. 1998 May; 21(3):170-80. View in: PubMed

Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S92-7. View in: PubMed

Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol. 1997 Sep; 158(3 Pt 1):740-5. View in: PubMed

Caring for children in foster care. J Pediatr Health Care. 1997 May-Jun; 11(3):127-9. View in: PubMed

Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Semin Urol Oncol. 1996 Nov; 14(4):230-6. View in: PubMed

Immunotherapy and gene therapy. Semin Urol Oncol. 1996 Nov; 14(4):237-43. View in: PubMed

Immunologic approaches to the treatment of cancer. Cancer Invest. 1995; 13(3):339-40. View in: PubMed

Early ambulation following lower extremity amputation. Rocky Mt Med J. 1968 Jul; 65(7):49-52. View in: PubMed

THE PARATHYROID CYST. REVIEW OF LITERATURE AND CASE REPORT. Rocky Mt Med J. 1965 Jul; 62:38-41. View in: PubMed

What price security? Rocky Mt Med J. What price security? Rocky Mt Med J. 1960 Nov; 57:55-61. View in: PubMed

Multiple foreign body ingestion. Rocky Mt Med J. 1955 Jul; 52(7):629-31. View in: PubMed

Powered bySC CTSI